the #FDA has approved Merck &amp; Co.'s #KEYTRUDA, as monotherapy for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) solid tumors, that have progressed following prior treatment  $MRK https://t.co/k9tAGh6b6k